Amr M. Yehia, Mahmoud G. Eldeib , Ahmed M. Mohamadin , Mohammed M. El-Zahabi
Introduction/Aims: assessment of the chemotherapeutic effect of zoledronic acid (ZA) when combined with 5-FU or Flutamide on prostate cancer cell line (PC-3), through estimation of synergistic effects of combinations on cytotoxicity, expression of miRNAs and apoptosis. Methods: cell viability was assessed by MTT assay. Different concentrations of combined ZA/5-FU and ZA/Flutamide were applied to PC-3 and were compared to single drug treatment for 48 h. Changes in miR-18a and miR-382 expressions after treatment were determined using quantitative real time-polymerase chain reaction (qRT-PCR). Immunofluorescence staining analysis was used to assess the changes in Bcl-2 and p53 expression. Results: IC50 of ZA, 5-FU, and Flutamide was 13.47 μM, 8.23 μM and 9.42 μM respectively. While the combination index (CI) of ZA/5-FU and ZA/Flutamide reached a level of synergistic effects at the combination of ¼ IC50 of each. The combination therapy was associated with over-expression of miR-382, down-expression of miR-18a, reduced Bcl-2 and enhanced p53 expressions. Conclusion: ZA/5-FU and ZA/Flutamide combinations offer interesting chemotherapeutic effects with lower doses and synergistic effects more than treatment with single drugs to be further investigated.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi